Drug Profile

MC 339

Alternative Names: MC-339

Latest Information Update: 02 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mariana Oncology
Class Antineoplastics; Peptides; Radioisotopes; Radiopharmaceuticals; Small molecules
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Small cell lung cancer

Most Recent Events

13 Sep 2024 Pharmacodynamics data from a preclinical studies in Small cell lung cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
11 Sep 2023 Preclinical trials in Small cell lung cancer in USA (Parenteral) before September 2023
07 Sep 2023 Mariana Oncology plans a clinical trial for Small cell lung cancer in 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com